Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.67 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.67 |
| ▸ | STAT3 | P40763 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | MIF | P14174 | 3/20 | 0.58 |
| ▸ | BCL2 | P10415 | 3/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869200 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22325167 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20242290 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL21333201 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL30189563 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20242552 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22326316 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22834201 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL21179283 | 0.99 | CRBN (0.69) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL30189483 | 0.99 | CRBN (0.69) | CRBNDDB1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734989-A2 | SYNTHESIS AND IN VITRO CHARACTERIZATION OF PROTEOLYSIS TARGETING CHIMERAS (PROTACS) FOR DEGRADATION OF DNA METHYLTRANSFERASE 1 (DNMT1) | Dana-Farber Cancer Institute, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-04-30 | — | — | US | disclosed |
| US-12569563-B2 | Selective HDAC6 degraders and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| US-20260028342-A1 | ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2026-01-29 | — | — | US | disclosed |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | NURIX THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3551185-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | Icahn School of Medicine at Mount Sinai (US) | 2019-10-16 | — | — | EP | disclosed |
| WO-2019170150-A1 | PROTEIN DEGRADATION TARGETING BCR-ABL COMPOUND AND ANTITUMOR APPLICATION THEREOF | 上海科技大学 | 2019-09-12 | — | — | WO | disclosed |
| WO-2019165189-A1 | PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165189-A1 | PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-08-22 | — | — | US | disclosed |
| WO-2019149922-A1 | COMPOUNDS WHICH CAUSE DEGRADATION OF EGFR, FOR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019144117-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES, LLC (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2018106870-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106870-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018089736-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | HIPK1, MCL1, HYPK | CRBN 421/4885DDB1 473/4885HDAC3 1077/4885 |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | IRAK1, IRAK2, IRAK3 | CRBN 71/4885DDB1 519/4885HDAC3 229/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | CRBN 149/4885DDB1 1222/4885HDAC3 180/4885 |
| US-20260028342-A1 | ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION | EEF1A2, EEF1E1, EEF1D | CRBN 3862/4885DDB1 1069/4885HDAC3 3381/4885 |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | TTK, ITK, CLK1 | CRBN 1072/4885DDB1 2640/4885HDAC3 1359/4885 |
| US-12569563-B2 | Selective HDAC6 degraders and methods of use thereof | HDAC6, HDAC1, HDAC11 | CRBN 405/4885DDB1 1138/4885HDAC3 4/4885 |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | CRBN 120/4885DDB1 350/4885HDAC3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.